Archives
-
Polybrene: An Assay-First Guide to Gene Delivery
2026-08-24
Polybrene, also known as Hexadimethrine Bromide, can improve viral gene delivery and difficult DNA transfection workflows. This assay-first guide connects its physicochemical mechanism with rigorous experimental design and lessons from the TRAP-1 mutant-p53 study.
-
Mithramycin A: From GC-Rich DNA to Translation
2026-08-23
Mithramycin A is an anticancer antibiotic that converts metal-dependent recognition of G-C-rich DNA into a practical strategy for studying transcription, c-myc regulation, and differentiation. This thought-leadership guide connects established leukemia and cancer biology research with a carefully bounded hypothesis around the miR-24-3p/Sp1/PI3K axis in doxorubicin-induced cardiac injury.
-
Rotigotine for Parkinson’s Disease Research
2026-08-22
Rotigotine is a dopamine D2/D3 receptor agonist that connects receptor pharmacology with neuroprotection, motor phenotyping, and continuous-delivery research. This workflow-focused guide shows how to select concentrations, separate symptomatic from protective effects, and troubleshoot solubility, vehicle, and exposure problems.
-
TRAP-1 Activates p53Y220C Through Chemical Proximity
2026-08-22
The reference preprint introduces TRAP-1, a chemical inducer of proximity that brings mutant p53Y220C into a ternary complex with BRD4 and restores transcription of p53 target genes. Its activity in pancreatic cancer cell models, together with inactive proximity-deficient controls, supports chemically induced proximity as a strategy for reactivating a mutated tumor suppressor.
-
EZ Cap EGFP mRNA 5-moUTP: Delivery Benchmark
2026-08-21
EZ Cap EGFP mRNA 5-moUTP provides a controlled enhanced green fluorescent protein mRNA payload for separating transcript quality from carrier performance. This article develops a delivery-benchmarking framework informed by engineered extracellular vesicle research rather than repeating standard reporter-assay protocols.
-
mCherry mRNA for Reliable Cell Assays
2026-08-20
Learn how mCherry mRNA and orthogonal viability controls can resolve inconsistent fluorescence, proliferation, and cytotoxicity results. This scenario-based guide explains where EZ Cap™ mCherry mRNA (5mCTP, ψUTP), SKU R1017, fits into reproducible workflows.
-
3-Aminobenzamide (PARP-IN-1) Workflow Guide
2026-08-20
Build reproducible PARP inhibition assays with 3-Aminobenzamide (PARP-IN-1), from oxidative-stress models to endothelial and diabetic nephropathy workflows. The guide combines practical dosing, controls, readouts, and troubleshooting with a cautious translation of coronavirus host-defense findings.
-
Rotavirus Infection and Nrf2 Redox Defense
2026-08-19
The reference study identifies a biphasic response in which rotavirus initially induces Nrf2 but later sharply reduces its abundance, nuclear presence, and transcriptional activity. Its experiments connect late Nrf2 loss to proteasome-associated, K48-linked ubiquitination rather than simply to oxidative imbalance, providing a mechanistic framework for studying viral disruption of antioxidant defense.
-
Romidepsin (FK228) in Proteomic Cancer Workflows
2026-08-19
Romidepsin (FK228) provides a selective class I HDAC perturbation for connecting chromatin remodeling with apoptosis, cell-cycle phenotypes, and proteomic changes. This guide shows how to position it beside the RFC4–Notch findings from a recent NSCLC study, while separating validated product characteristics from practical workflow recommendations.
-
Pemetrexed: From Folate Stress to Precision Oncology
2026-08-18
Pemetrexed is more than a cytotoxic benchmark: its coordinated disruption of folate-dependent nucleotide synthesis creates a mechanistic framework for studying tumor state, DNA repair, and treatment response. This translational guide connects pemetrexed disodium assay design with Borchert et al.’s findings on BRCAness in malignant pleural mesothelioma, while outlining biomarker-aware strategies for cancer chemotherapy research.
-
Dual-Action p38α MAPK Inhibition and Dephosphorylation
2026-08-18
The reference preprint shows that some kinase inhibitors do more than occupy the p38α active site: they also reshape the activation loop to accelerate dephosphorylation by WIP1. By combining biochemical assays with X-ray crystallography, the study establishes a mechanism that could improve inhibitor potency and specificity, while leaving disease-model translation for future testing.
-
TMEM16F, Ferroptosis, and Tumor Immune Rejection
2026-08-17
Yang et al. identify TMEM16F-mediated plasma-membrane lipid scrambling as an execution-stage suppressor of ferroptosis. By linking phospholipid redistribution, membrane tension, lytic death, danger signaling, and PD-1 response, the study suggests that blocking lipid scrambling can convert ferroptotic stress into a stronger antitumor immune stimulus.
-
Separating Growth Inhibition from Cancer Cell Death
2026-08-17
Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for distinguishing proliferative arrest from true cell killing, improving interpretation of in vitro experiments and the design of translational cancer models.
-
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-08-16
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to improve the apparent aqueous solubility of poorly soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. It is appropriate for validated pharmaceutical and biochemical solubility workflows, but should not be treated as evidence of clinical efficacy, universal bioavailability improvement, or suitability for applications outside the documented excipient and solubilization scope.
-
YAP-TEAD Control of Surface Ectoderm Super-Enhancers
2026-08-15
The reference study maps how super-enhancers and three-dimensional chromatin contacts coordinate early surface ectoderm commitment from pluripotent stem cells. Its functional experiments identify YAP-TEAD, particularly TEAD activity, as an upstream regulator that promotes early super-enhancer establishment and activation of lineage-associated genes.